Novartis evidence on ‘step change’ Jakavi not yet enough for NICE
This article was originally published in Scrip
Executive Summary
Novartis has so far failed to convince NICE, the health technology appraisal institute, to recommend for use on the National Health Service the firm's JAK inhibitor, Jakavi (ruxolitinib). Even though the institute recognized that Jakavi was an innovative treatment for patients with splenomegaly and myelofibrosis, there were uncertainties in the evidence, including missing data, according to draft guidance issued on 13 February. That means that a second appraisal committee must now take place on 13 March. Carole Longson, director of NICE's Health Technology Evaluation Centre urged "all those with an interest in myelofibrosis" to comment via the NICE website.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.